BioCardia

BioCardia ROE

The Return on Equity (ROE) of BioCardia (BCDA) as of Nov 20, 2026 is -919.33 %. In the previous year, Return on Equity (ROE) was -949.34 % — a change of -3.16% (higher).

ROE

-919.33 %

YoY

-3.16%

Last updated:

In 2025, BioCardia's return on equity (ROE) was -919.33 %, a -3.16% increase from the -949.34 % ROE in the previous year.

The BioCardia ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-368.86 USD
Jan 1, 2019
-620.63 USD
Jan 1, 2020
-78.24 USD
Jan 1, 2021
-121.65 USD
Jan 1, 2022
-243.52 USD
Jan 1, 2023
721.83 USD
Jan 1, 2024
-949.34 USD
Jan 1, 2025
-919.33 USD
The BioCardia ROE history
YEARROEYoY
-919.33 %-3.16%
-949.34 %-231.52%
721.83 %-396.42%
-243.52 %+100.18%
-121.65 %+55.47%
-78.24 %-87.39%
-620.63 %+68.26%
-368.86 %+233.40%
-110.63 %+120.86%
-50.09 %-2,257.08%
2.32 %+34.41%
1.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

ROE Details

Decoding BioCardia's Return on Equity (ROE)

BioCardia's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing BioCardia's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

BioCardia's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in BioCardia’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about BioCardia stock

Return on Equity (ROE) of BioCardia is -919.33 % in 2025.

Return on Equity (ROE) of BioCardia changed from -949.34 % to -919.33 %, representing a -3.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) BioCardia since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s BioCardia with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioCardia

All Key Metrics — BioCardia